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ABSTRACT
Bone loss resulting from degenerative diseases and trauma is a significant clinical 
burden which is likely to grow exponentially with the aging population. In a number of 
conditions where pre-formed materials are clinically inappropriate an injectable bone 
forming hydrogel could be beneficial. The development of an injectable hydrogel to 
stimulate bone repair and regeneration would have broad clinical impact and economic 
benefit in a variety of orthopedic clinical applications. 
We have previously reported the development of a Laponite® crosslinked pNIPAM-
co-DMAc (L-pNIPAM-co-DMAc) hydrogel delivery system, loaded with hydroxyapatite 
nanoparticles (HAPna), which was capable of inducing osteogenic differentiation 
of mesenchymal stem cells (MSCs) without the need for additional growth factors  
in vitro. However to enable progression towards clinical acceptability, biocompatibility 
and efficacy of the L-pNIPAM-co-DMAc hydrogel to induce bone repair in vivo must 
be determined. 
Biocompatibility was evaluated by subcutaneous implantation for 6 weeks in 
rats, and efficacy to augment bone repair was evaluated within a rat femur defect 
model for 4 weeks. No inflammatory reactions, organ toxicity or systemic toxicity 
were observed. In young male rats where hydrogel was injected, defect healing 
was less effective than sham operated controls when rat MSCs were incorporated. 
Enhanced bone healing was observed however, in aged exbreeder female rats where 
acellular hydrogel was injected, with increased deposition of collagen type I and 
Runx2. Integration of the hydrogel with surrounding bone was observed without the 
need for delivered MSCs; native cell infiltration was also seen and bone formation 
was observed within all hydrogel systems investigated. 
This hydrogel can be delivered directly into the target site, is biocompatible, 
promotes increased bone formation and facilitates migration of cells to promote 
integration with surrounding bone, for safe and efficacious bone repair.
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INTRODUCTION
Bone loss resulting from degenerative diseases and 
trauma is a significant clinical burden which is likely to 
grow exponentially with the aging population [1]. Bone 
autografts are considered the gold standard treatment 
for bone repair; however, this is hampered by limited 
availability and donor-site morbidity [2]. Allografts are 
more readily available but can result in immunogenicity 
and poor outcomes [3, 4]. Consequently, there is a growing 
clinical need for the development of novel synthetic bone 
grafting materials which can substitute and augment bone 
effectively [5, 6]. A variety of bone substitute materials 
including: ceramics [7, 8] and metals [9] have been used 
therapeutically. However, these are synthesised as pre-
formed constructs, and normally implanted by invasive 
surgery increasing operative risk. 
Hydrogels, are a group of biomaterials which may 
overcome these limitations as they can be administered 
in a minimally invasive manner and fill complex cavities 
in vivo [10]. Recently Lohmann et al., 2017 reported the 
use of a 3D architectured hydrogel in vivo, within a rat 
calvarial defect, which displayed significant promise 
for bone regeneration comparable with autologous bone 
grafts [11]. However, similarly to the clinical bone 
grafts that are currently available, this hydrogel was 
implanted as pre-formed discs [11]. Temperature sensitive 
hydrogels are attractive since they can be applied as a 
liquid directly into the defect site, before in situ gelation 
at body temperature [12]. Furthermore, hydrogels enable 
the incorporation of bioactive factors such as calcium-
based minerals to enhance scaffold mineralisation and 
osteogenicity [13–16]; they also facilitate the delivery 
of regenerative cells such as mesenchymal stem cells 
(MSCs) [17–19], the combination of these factors 
may provide intrinsic osteogenic capabilities [20]. 
Studies have also shown that substrate stiffness and 
nanotopography can influence cell attachment, function 
and differentiation [21–24]. The incorporation and 
delivery of MSCs within a suitable hydrogel would not 
only serve to maintain the delivered MSCs at the injection 
site, but could also promote integration with surrounding 
bone tissue and provide a micronevrimonent surrounding 
the cells to modulate their osteogenic differentiation. A 
major drawback of hydrogels is that they do not possess 
the mechanical robustness to be used in load bearing 
applications [25], however their use in a variety of non-
weight bearing orthopedic situations could be beneficial 
particularly where pre-formed materials are clinically 
inappropriate or challenging. Applications could include: 
i) augmenting bone around dental implants and for 
treatment of bone defects in patients with periodontal 
disease which affects 45% of adults moderately and 
5% of adults severely within the UK [26]; ii) increasing 
bone density in osteoporosis which affects 3 million in 
the UK [27, 28]; iii) aiding in the repair of non-union 
fractures which cost the NHS ~£7000-£79,000 per patient 
[29], finally, iv) such an approach could be utilised to 
improve fixation of prosthetic joints that have loosened 
due to osteolysis [30]. In addition, the use of an injectable 
hydrogel, with intrinsic osteogenic capacity, could be 
beneficial in certain load bearing bone applications. 
For example, to improve and accelerate internal bone 
fixation and integration of bone cages such as those used 
in clinical practice for intervertebral disc fusion [31]. 
The development of an injectable hydrogel to stimulate 
bone repair and regeneration would therefore have 
broad clinical impact and economic benefit in a variety 
of orthopedic clinical applications. An ideal injectable 
bone graft hydrogel, would be one with: low viscosity for 
minimally invasive delivery; can fill complex voids in 
vivo before rapid in situ gelation; be biocompatible and be 
osteoconductive to promote integration. To date, hydrogel 
systems incorporated with MSCs have been reported for 
bone regeneration (Supplementary Table 1); however 
few of these are injectable and the majority require the 
addition of growth factors to stimulate osteogenesis, 
adding both complexity and cost to the treatment strategy 
[32–36].
We have previously reported the development 
of a synthetic Laponite® crosslinked pNIPAM-co-
DMAc hydrogel (L-pNIPAM-co-DMAc) loaded with 
hydroxyapatite nanoparticles (HAPna), which induces 
osteogenic differentiation of MSCs in vitro, without 
the need for osteogenic growth factors [18]. This 
synthetic hydrogel is clinically appealing for bone 
repair since it is cytocompatible in the liquid state and 
therefore enables the safe incorporation and delivery 
of MSCs. The hydrogel undergoes rapid gelation at 
body temperature and the synthesis does not require 
the addition of chemicals for gelation or clean-up [18, 
37]. The combination of all of these properties in one 
hydrogel system is unlike any other hydrogel system for 
bone repair previously developed. The clinical success 
of this hydrogel is dependent on the safe delivery of the 
scaffold and incorporated MSCs; maintenance within the 
defect site; integration with surrounding bone tissue; and 
the capacity to stimulate bone repair within an in vivo 
bone defect. 
This study investigated the biocompatibility 
in vivo following rat subcutaneous implantation and 
biocompatibility and efficacy following injection into a 
rat femur defect model. L-pNIPAM-co-DMAc hydrogels 
with and without rat MSCs and HAPna were investigated 
to test the hypothesis that the delivery of MSCs within 
L-pNIPAM-co-DMAc, with incorporated HAPna, would 
aid scaffold integration as well as promote and accelerate 
bone healing. 
Oncotarget18279www.oncotarget.com
RESULTS
In vivo safety: subcutaneous implantation
Gross examination of organs and implantation site
All animals, in all experimental groups and sham 
operated controls, survived the subcutaneous implantation 
surgery and 6 weeks postoperative course without any 
surgery-related or implantation-related complications. 
The animal weight was recorded before surgery and 
immediately following sacrifice. Overall the weight of all 
animals increased slightly indicating good post-operative 
development and healthy status of all animals (data not 
shown). Following animal sacrifice, the liver, kidney, 
testes and lymph nodes were extracted; no gross evidence 
of infection or organ toxicity was observed in any animal 
(data not shown). Gross examination of implantation sites 
demonstrated encapsulation of hydrogel constructs by 
surrounding tissues (Figure 1A, 1B). No gross differences 
were observed between hydrogel formulations or sham 
operated animals (Figure 1A–1C). The tissue surrounding 
and encapsulating the hydrogel was macroscopically 
healthy with no signs of infection, inflammation or 
vascularisation (Figure 1A, 1B). 
Histological evaluation of organs and implantation 
site
Histopathological assessment of the implantation 
site was performed to investigate hydrogel integrity and 
local tissue response following subcutaneous implantation 
of hydrogel scaffolds (Figure 1D–1F). All hydrogels 
remained in place where implanted, with no evidence of 
angiogenesis, granulation tissue or inflammatory response 
(Figure 1D, 1E). Hydrogels were surrounded by fibrous 
connective tissue with no evidence of hydrogel degradation 
(Figure 1D, 1E). Calcium deposition, confirmed via 
alizarin red staining, was observed within the hydrogel 
region of 10 animals (Figure 1G–1I, and Supplementary 
Table 2), independent of which hydrogel formulation 
was implanted (Figure 1G–1I and Supplementary Table 
2). Haematoxylin and eosin stained liver, kidney, testes 
and lymph node sections displayed normal histological 
appearance with no evidence of infection or toxicity in 
any animal (Supplementary Figure 1).
Blood and biochemistry analysis
Blood samples were extracted from animals 
following sacrifice and full blood count, differential blood 
count and serum biochemistry was performed (Figure 
1J–1O). No significant differences in haematological and 
serum biochemistry parameters were seen between any 
animals in any test group compared to sham operated 
controls, indicating no signs of systemic inflammatory 
response or organ toxicity (Figure 1J–1O).
In vivo efficacy: femur defect model in 10–12 
weeks old male Wistar rats
All animals survived surgery and the 4 week 
postoperative course without complications. The average 
weight of all animals increased slightly indicating good 
post-operative development and healthy status of animals. 
Furthermore no gross or histological evidence of infection 
or organ toxicity was observed in any animal.
Micro CT analysis of femur defect region in young 
male rats
Percentage bone volume (% bv), as an end point 
measure of bone formation within the femur defect region, 
was assessed using Micro-CT (Figure 2A). No significant 
difference in % bv was observed in young male Wistar 
rats between sham operated animals and hydrogel injected 
groups (Figure 2A). However a decreasing trend in the 
% bv was observed in young male Wistar rats where 
L-pNIPAM-co-DMAc (±HAPna) incorporated with MSCs 
had been injected (Figure 2A).
Histological evaluation of femur defect region in 
young male rats
Histopathological analysis of the femur defect site 
in young rats was performed to assess the bone healing 
response and local tissue response. All three sham 
operated controls displayed almost complete healing, with 
newly regenerated immature bone matrix found within 
the defect region (Figure 3). L-pNIPAM-co-DMAc was 
observed within the defect region in all animals where 
it had been injected regardless of whether HAPna and/
or MSCs were incorporated (Figure 3). L-pNIPAM-co-
DMAc integrated with the surrounding bone tissue with 
no evidence of fibrous encapsulation (Figure 3). No 
histological evidence of toxicity or inflammatory response 
were observed (Figure 3). In general where L-pNIPAM-
co-DMAc was injected, regardless of whether HAPna or 
MSCs were incorporated, the regeneration of new bone 
matrix was evident in association with the hydrogel 
(Figure 3). However the hydrogel was seen to disrupt the 
cortical plate, delaying healing in comparison to sham 
operated controls (Figure 3). Where acellular L-pNIPAM-
co-DMAc with HAPna was injected, the defect region 
healed well, with bone formation observed in association 
with the hydrogel and infiltration of numerous osteoblast 
like cells (Figure 3). Where L-pNIPAM-co-DMAc with 
incorporated MSCs (±HAPna) had been injected, the 
healing response was histologically less effective, with 
large voids showing no evidence of newly regenerated 
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Figure 1: In vivo safety analysis following 6 weeks. (A, B) Macroscopic images following 6 weeks after subcutaneous implantation 
of L-pNIPAM-4h hydrogel (A) and L-pNIPAM-co-DMAc-4h hydrogel (B). Black arrows indicate hydrogel encapsulated by the 
surrounding tissue. (C) Macroscopic image of sham operated control following 6 weeks. (D, E) haematoxylin and eosin (H&E), of (D) 
L-pNIPAM-4h hydrogel and (E) L-pNIPAM-co-DMAc-4h hydrogel following 6 weeks. (F) H&E of sham operated control following 6 
weeks. (G) Representative microscopic image stained with alizarin red (AR) demonstrating where calcium deposits were observed within 
L-pNIPAM-4h hydrogel region. (H) Representative microscopic image stained with AR demonstrating where calcium deposits were not 
observed within L-pNIPAM-co-DMAc-4h hydrogel region. (I) AR staining of sham operated control. Scale bar 100 µm. (J–O) Blood and 
biochemistry analysis. Graphs shown include: lymphocytes, haemoglobin, creatine, alanine transferase (ALT), alkaline phosphatase (ALP) 
and C-reactive protein (CCRP). 
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bone matrix, present in the defect region 4 weeks post 
implantation (Figure 3). 
Micro CT analysis of femur defect region in 
young vs aged sham operated controls
To test the hypothesis that: aged (>6 months) female 
exbreeder rats would have a reduced or delayed healing 
capacity, Micro-CT analysis of the femur defect after 4 weeks 
was performed on sham operated controls in young males (n 
= 7) and aged female ex-breeder Wistar rats (n = 7) (Figure 
2B). One young control was excluded due to pre-existing 
femur pathology. The % bv within the femur defect site of 
young male Wistar rats in the sham operated control group 
was significantly higher (P = 0.0002) than that of the aged 
female exbreeder rats 4 weeks post operation (Figure 2B).
In vivo efficacy: femur defect model in aged (>6 
months) female ex-breeder Wistar rats
All aged female ex-breeder Wistar rats in 
the different hydrogel scaffold groups and sham 
operated control group survived surgery and the 4 
weeks postoperative course. One animal injected with 
L-pNIPAM-co-DMAc +MSC +HAPna, was excluded as 
no visible defect following 4 weeks could be seen using 
Micro-CT or histological analysis, as such the region of 
interest could not be objectively selected. 
Micro CT analysis of femur defect region in aged  
(>7 months) female ex-breeder Wistar rats
No significant difference in the % bv was observed 
between ex-breeder female Wistar rats in the hydrogel 
scaffold injected groups and sham operated control group 
(Figure 2B).
Histological evaluation of femur defect region in 
female ex-breeder rats
Within the sham operated controls, two animals 
displayed effective healing of the femur defect; whilst 
fibrous tissue was observed overlying the defect region 
with little histological evidence of bone healing in the 
remaining four animals. In general where L-pNIPAM-
co-DMAc was injected, regardless of whether HAPna or 
MSCs were incorporated, the hydrogel integrated with 
the surrounding bone tissue with no evidence of fibrous 
encapsulation (Figure 4A). No histological evidence of 
toxicity or inflammatory response towards the injected 
hydrogels was observed in any animal (Figure 4A). 
L-pNIPAM-co-DMAc was observed within the defect 
region in all animals where it had been injected (Figure 
4A). Bone regeneration was confined to the bone cortex 
region in sham operated controls. However collagen 
deposition, as identified via Masson’s trichrome staining, 
and newly regenerated bone matrix, extended past the 
femur cortex and into the bone marrow space where 
the hydrogel was injected (Figure 4A, 4B). The healing 
response between sham operated controls and hydrogel 
injected animals was found to be histologically distinct. 
Within sham operated controls, bone regeneration was 
initiated from the cortical plate around the periphery of 
the defect region and healed towards the centre (Figure 
4A). In contrast where L-pNIPAM-co-DMAc had been 
injected, the bone repair was initiated in the centre of 
the defect region in direct association with the injected 
hydrogel (Figure 4A). Where acellular L-pNIPAM-
co-DMAc, without HAPna, was injected, 5/7 animals 
displayed effective healing across the entire width of 
the defect region. However hydrogel was also located 
outside the defect region which was not associated with 
bone remodelling (Figure 4A). Where L-pNIPAM-co-
Figure 2: Bone volume (%) assessed using Micro-CT. (A) Pilot study with 10–12 week (young) male white Wistar rats (n = 3). 
(B) Control 10–12 week (young) male white Wistar rats (n = 6), compared with older (>7 months) exbreeder female white Wistar rats 
(n = 7). * indicates statistical signiicance (P ≤ 0.05).
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DMAc + HAPna was injected, both with and without 
incorporated MSCs, the hydrogel was observed within the 
centre of the defect region in all animals and was found 
to be associated with newly regenerated bone matrix 
(Figure 4A). No histological evidence of enhanced repair 
with the incorporation of MSCs within L-pNIPAM-co-
DMAc + HAPna was observed in comparison to the 
injection of acellular L-pNIPAM-co-DMAc + HAPna 
(Figure 4A).
Assessment of collagen deposition within the femur 
defect within aged female ex-breeder Wistar rats
Masson’s trichrome staining, to assess collagen 
deposition as an early matrix marker of bone formation, 
was performed on tissue sections within the femur defect 
region of aged female Wistar rats (Figures 4B, 5). Cellular 
and matrix collagen staining in the centre of the defect 
region was observed histologically in association with 
L-pNIPAM-co-DMAc in all cases (Figure 4A). Where 
L-pNIPAM-co-DMAc + HAPna (±MSCs) (P = 0.0085 
without MSCs, P = 0.0197 with MSCs) was injected, the 
percentage area of collagen staining was significantly 
increased in the centre of the defect region in comparison 
to sham operated controls (Figure 5). No significant 
difference in the percentage area of collagen staining was 
observed where acellular L-pNIPAM-co-DMAc, without 
HAPna, was injected in comparison to sham operated 
controls (Figure 5). No significant difference in the percent 
area of collagen staining was observed within the defect 
Figure 3: In vivo rat femur defect study in 10–12 week old male white Wistar rats. H&E and Masson’s trichrome as well as 
3D Micro-CT reconstructed images of the femur defect site following 4 weeks repair time. Scale bar 1000 µm.
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area between acellular L-pNIPAM-co-DMAc+HAPna 
with and without incorporated MSCs (Figure 5). 
Immunohistochemistry evaluation of the femur defect 
within aged female ex-breeder rats
Immunohistochemistry was utilised to determine 
protein expression for the macrophage marker: CD68; 
the early bone markers: runx2 and alkaline phosphatase; 
the bone matrix markers: collagen type I and collagen 
type X; as well as the late bone markers osteopontin and 
osteocalcin to assess the bone healing response within 
the rat femur defect model following 4 weeks repair time 
(Figure 6). The macrophage marker (CD68), was only 
expressed by a few cells within the defect region of both 
sham operated control and hydrogel injected animals 
with no difference in expression observed between the 
different experimental groups (Supplementary Figure 
2). The osteoblast specific transcription factor runx2 
was expressed by cells within the defect region in all 
Figure 4: Histological assessment of the defect site after 4 weeks repair time following a non-critical sized defect in the midshaft of the 
femur in exbreeder female (>6 months old) rats, stained with H&E (A) or Masson’s trichrome (B). Representative images from 6 replicates 
for each experimental group to demonstrate the best, mid and worst bone repair observed from independent pathological assessment. Scale 
bar: 1000 µm.
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animals, however increased immunopositivity for runx2 
were observed in L-pNIPAM-co-DMAc injected defects 
in comparison to sham operated controls (Figure 6). The 
highest immunopositivity for runx2 was observed in 
animals where L-pNIPAM-co-DMAC with incorporated 
MSCs was injected (Figure 6). Immunopositive cellular 
and matrix staining for alkaline phosphatase and collagen 
type I, both early markers of bone regeneration, were 
highly expressed across the entire width of the defect 
region in 2/6 sham operated controls, where effective 
healing occurred (Figure 6). However, in the remaining 
4/6 animals, where incomplete healing occurred, limited 
matrix immunopositivity for alkaline phosphatase and 
collagen type I were observed (Figure 6). Intense cellular 
and matrix staining for alkaline phosphatase and collagen 
type I was observed throughout the defect region in all 
animals where L-pNIPAM-co-DMAc had been injected, 
regardless of whether HAPna and/or MSCs were 
incorporated (Figure 6). Immunopositive matrix staining 
for collagen type I was observed in the same position as 
the collagen staining observed via Masson’s trichrome. 
Collagen type X, was also expressed within the defect 
region of all animals, however increased immunopositivity 
were identified histologically in sham operated controls 
in comparison to L-pNIPAM-co-DMAc injected 
animals (Figure 6). High levels of immunopositivity for 
osteopontin and osteocalcin were observed in 2/6 sham 
operated controls where effective healing was evident; 
however in the 4 remaining sham operated controls and 
L-pNIPAM-co-DMAc injected animals, low levels of 
cellular staining for both late phase bone markers were 
observed (Figure 6). 
FTIR analysis of femur defect region in female 
exbreeder rats
FTIR imaging was performed to determine the 
location of the L-pNIPAM-co-DMAc within each bone 
section and was achieved by plotting the integrated 
intensity of infrared peaks specific to the different 
components within the sample. The amide I peak (~1660 
cm-1) was used to elucidate the location of the bone tissue, 
but no attempt was made to distinguish between the 
different bone matrix species. The peak associated with 
the carbonyl of the DMAc comonomer was used to show 
the prevalence of the hydrogel and the C-H bending mode 
~1460 cm-1 was used to determine the distribution of the 
embedding wax (Supplementary Figure 3).
There was no evidence of any hydrogel in the 
control sample (Figure 7). Images generated for the 
samples that were injected with L-pNIPAM-co-DMAc, 
with or without HAPna and/or MSCs, showed co-
localisation of the hydrogel and bone tissue within the 
defect zone indicating good integration with the newly 
formed bone tissue (Figure 7).
DISCUSSION
Tissue engineering strategies which combine matrix 
secreting cells with a functional support scaffold, offer a 
Figure 5: Percentage area of collagen staining (blue) within the femur defect site from histological sections stained 
with Masson’s trichrome, in exbreeder female (>6 months old) rats. * indicates statistical signiicance (P = ≤ 0.05). 
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promising alternative to autologous bone grafts for repair 
of bone defects. The aim of this study was to evaluate the 
safety and efficacy of L-pNIPAM-co-DMAc containing 
HAPna and MSCs, within a rat non-critical sized femur 
defect model following 4 weeks repair time. The femur 
defect model used in this study is a self-healing defect 
and therefore enables the evaluation of whether the 
hydrogel could promote and accelerate bone repair, in 
comparison to the native animal healing response. We 
evaluated several clinical requirements within the femur 
defect model, including: biocompatibility; injection of 
the hydrogel; maintenance of the hydrogel within the 
defect region; integration with surrounding bone tissue 
as well as the osteogenic potential to differentiate MSCs 
into bone matrix secreting cells for the regeneration and 
augmentation of bone tissue. 
L-pNIPAM-co-DMAc biocompatiblity and 
delivery
The clinical translation of suitable bone graft 
materials is reliant on excellent biocompatibility [38, 39]. 
The pre-set hydrogel constructs subcutaneously implanted 
in this study were shown to be biocompatible, with no 
evidence of a local or systemic inflammatory response, 
or organ toxicity. Hydrogel constructs were shown to 
be biocompatible regardless of whether the copolymer, 
DMAc, was incorporated to tailor the gelation temperature 
Figure 6: Immunohistochemistry assessment of the defect site in exbreeder female (>6 months old) rats. Scale bar: 200 µm.
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of the hydrogel to 37° C. Furthermore, reduction of the 
polymerisation time from 24 h to 4 h, reducing the overall 
synthesis duration, did not affect biocompatibility. In 
addition, no evidence of toxicity or inflammation was 
observed where L-pNIPAM-co-DMAc, with and without 
incorporated HAPna and MSCs, were injected as a liquid 
into the femur defect, before in situ gelation. Many 
hydrogel systems, previously reported, have not been 
fully reacted prior to injection, requiring co-injection with 
crosslinking agents [40–42]; this raises significant safety 
concerns to surrounding tissues during hydrogel delivery 
and precludes the incorporation of regenerative cells. The 
biocompatibility of L-pNIPAM-co-DMAc in the liquid 
and gelled state, demonstrated here in vivo, is extremely 
promising for patient administration as it provides the 
capacity for cell delivery and minimally invasive injection. 
This reduces operative risk and minimises the surgical 
disturbance of surrounding tissues associated with the 
implantation of bone graft materials [43, 44]. Gelation 
of L-pNIPAM-co-DMAc at physiological temperature, 
within the bone defect, is advantageous over numerous 
photo-crosslinkable hydrogels developed for bone repair. 
As the use of UV light to induce in situ gelation poses 
safety concerns to both delivered cells and surrounding 
tissues during administration [45, 46]. 
One of the major concerns of injectable biomaterials, 
particularly with incorporated stem cells with potency to 
differentiate into multiple cell types, is controlling the 
location of biomaterial and delivered cells following 
injection [46, 47]. All L-pNIPAM-co-DMAc hydrogels, 
demonstrated rapid gelation (<5 s) and were still 
maintained within the bone defect in all animals after 4 
weeks. However, newly regenerated bone matrix extended 
past the bone cortex region and within the bone marrow 
space where the hydrogel had been injected. It is essential 
that hydrogels delivered as liquids are injected with 
precision within the defect location to prevent spillage and 
leakage to surrounding tissues [48, 49]; however within 
the femur defect model, the bone injury spans the entire 
thickness of the cortex and leaves the bone marrow cavity 
space exposed. It is likely that L-pNIPAM-co-DMAc 
will be most suitable for applications to fill bone defects 
in clinical cases of osteoporosis, smaller bone fractures 
where irregular shaped defects are contained within intact 
bone, within spinal fusions where spinal cages are used 
providing a contained space and periodontal regenerative 
therapy [43, 50]. 
Efficacy of L-pNIPAM-co-DMAc for bone 
augmentation
The ability of L-pNIPAM-co-DMAc, ± HAPna 
and MSCs, to promote and accelerate bone healing 
within a self-healing femur defect model, was evaluated 
to determine clinical efficacy for bone repair. Successful 
bone regeneration is reliant on the presence of bone 
matrix secreting cells, either differentiated osteoblasts 
or MSCs which have the ability to differentiate into 
Figure 7: Representative FTIR tissue distribution map of a transverse section within the defect region of parafin 
embedded rat femur. Overlapping regions displayed between bone tissue (Amide group- 1661 cm-1) and the pNIPAM-co-DMAc 
hydrogel (identiied via the carbonyl group on DMAc 1738 cm-1). Distribution map of wax (1483 cm-1) also included as a control. 
Oncotarget18287www.oncotarget.com
osteoblasts dependant on their surrounding environmental 
cues. It is therefore critical that the hydrogel is able to 
act as an osteoinductive extracellular matrix support 
which facilitates the adhesion and infiltration of these 
cells. Unlike previous materials where cell penetration 
has been an issue [51], native osteoblast cells were 
observed histologically within the centre of the acellular 
L-pNIPAM-co-DMAc ± HAPna, in all animals where 
it had been injected. This osteoblast cell infiltration is 
essential not only for deposition of newly regenerated bone 
matrix, but also to support graft integration with adjacent 
bone tissue. Biomaterial osteointegration is essential to 
prevent graft extrusion and provide a functional bone/
scaffold matrix with optimum mechanical performance 
[52, 53]. Unlike previous polymeric bone implants 
which became encapsulated by fibrous tissue following 
implantation [54], L-pNIPAM-co-DMAc was found to 
integrate with surrounding bone tissue in all animals, 
regardless of whether HAPna or MSCs were incorporated. 
In young male rats, where L-pNIPAM-co-DMAc 
was injected, defect repair was less effective where MSCs 
had been injected. MSC delivery, to induce regeneration 
of bone defects, has been investigated in vivo in many 
bone defect models, with positive results [55, 56]. The 
less effective healing response observed in young male 
rats where MSCs were injected could be due to the ex vivo 
culture and expansion of MSCs performed in this study 
prior to implantation. This may have resulted in an altered 
MSC cell phenotype, similar to the reduced osteogenic 
differentiation capacity and bone forming ability from 
MSCs cultured ex vivo prior to transplantation reported 
in other studies [57, 58]. It is also possible that delivered 
MSCs failed to survive since expanded MSCs have been 
shown in vivo to lose their immunosuppressive activity 
following implantation and subsequently be destroyed [38, 
59]. It is likely that the MSCs transplanted within young 
male rats in this study were not required to accelerate 
native bone healing since the femur defect model spans 
the entire bone cortex, exposing the bone marrow space 
where there is a large population of native MSCs to aid 
in bone matrix repair. The transplanted MSCs utilised in 
this study were not autologous to the animal recipient and 
therefore would have needed to adapt and survive within 
the defect environment. Only then can they differentiate 
into osteoblasts, depositing newly regenerated bone matrix 
and this may have resulted in a delayed healing response. 
However, in a non-union defect or in individuals whom 
have a defective bone healing response, due to either 
age or disease, implanted MSCs may still be required to 
promote the initial stages of bone repair. 
To better reflect the aged target population typically 
afflicted by impaired bone healing, the femur defect was 
performed within aged (>6month) female ex-breeder 
rats. Bone healing of the femur defect in aged female 
ex-breeder rats was confirmed to be less effective in 
comparison to young male rats, with a significantly lower 
% bv within the defect region, following 4 weeks repair 
time in sham operated controls. This is in agreement with 
the delayed bone healing in both aged [60] and female 
[61] rats previously reported [3]. 
Regeneration of mature mineralised bone tissue 
is reliant on the orchestrated production and deposition 
of several matrix proteins which become organised into 
a unique anisotropic hierarchical structure [62]. Bone 
tissue formation is initiated by differentiation of MSCs to 
osteoblasts that synthesise and deposit collagen type I, the 
main extracellular matrix component of bone tissue [63]. 
Histologically, enhanced matrix deposition and healing 
was found within hydrogel injected defects in comparison 
to sham operated controls with increased deposition 
of the osteoblast specific transcription factor runx2, as 
well as the early bone markers alkaline phosphatase and 
collagen type I. In contrast only low levels of expression 
for the late bone markers osteopontin and osteocalcin, 
were observed. This suggests that the matrix repair that 
had taken place was early on in the bone regeneration 
process. All L-pNIPAM-co-DMAc formulations were 
shown to increase deposition of collagen staining which 
could indicate promotion of initial stages of bone repair, 
however 4 weeks post operation was not long enough for 
the production of a fully mature mineralised bone matrix. 
The impaired healing capacity of aged ex-breeder rats 
[60], as well as potentially a reduced regenerative capacity 
of native MSCs and delivered MSCs [64–67], extracted 
from these animals, is likely to be the reason that complete 
repair of the defect site was not seen by 4 weeks with 
no significant difference observed in the bone volume 
fraction on Micro-CT analysis. 
Bone healing in general is initiated at the peripheral 
margins of bone defects [63], as was observed within sham 
operated controls. However, where L-pNIPAM-co-DMAC 
was injected, the mechanism of bone repair appeared to be 
different, with newly regenerated bone observed in direct 
association with the hydrogel in the centre of the femur 
defect. This alternative repair may be clinically beneficial 
in patients with impaired healing, where bone regeneration 
initiated at the peripheral margins is insufficient and 
delayed. 
The healing response within the femur defect 
region between the different hydrogel injected groups 
was histologically indistinct following 4 weeks repair 
time. Recently Hayashi et al., 2016 reported that in vivo 
bone repair, using a nanofiber hydrogel, was reliant 
on the incorporation of stem cells. In this study, bone 
repair was initiated in the centre of the femur defect even 
where acellular L-pNIPAM-co-DMAC ± HAPna was 
injected and migration of native cells was observed. This 
suggests that the hydrogel could offer clinical benefit 
even in the absence of cells [67]. However increased 
runx2 immunopostivity was observed where MSCs 
were incorporated within L-pNIPAM-co-DMAC with 
HAPna, suggesting improved osteogenicity with the 
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delivery of MSCs, in agreement with previous studies 
[35, 68]. Effective bone repair and scaffold integration 
was evident where L-pNIPAM-co-DMAc without 
HAPna had been injected, indicating that the addition 
of HAPna is not essential within L-pNIPAM-co-DMAc 
for bone augmentation. This is likely due to the fact that 
the hydrogel was injected within a bone defect location 
and was exposed to the native osteogenic biological 
cues and mechanical forces required to stimulate bone 
healing. However where L-pNIPAM-co-DMAc was 
injected without HAPna, hydrogel which was not 
associated with bone remodelling was also located on the 
outside of the defect region, suggesting local signalling 
drives osteogenesis only in close proximity to the bone. 
Moreover, we have also previously demonstrated that the 
addition of HAPna within L-pNIPAM-co-DMAc is critical 
to ensure correct osteogenic cell differentiation in vitro 
[18, 37, 53].  
Considerations for the clinical translation of 
L-pNIPAM-co-DMAc for bone repair
One of the major concerns with the use of hydrogels 
for bone repair is their associated weak mechanical 
properties [39]. In the present study, L-pNIPAM-co-
DMAc was mechanically sufficient to provide adequate 
support for continued animal activity following the femur 
defect. However, the femur defect was not of a critical 
size and therefore the load bearing forces applied to the 
scaffold do not reflect those that the scaffold would need 
to withstand within a large critically sized bone defect. In 
general for larger bone defects the use of L-pNIPAM-co-
DMAc is likely to be mechanically insufficient in early 
repair stages, but may be applied as an osteogenic cell 
delivery vehicle, in combination with an additional support 
structure to stimulate bone regeneration and promote graft 
integration. Within the femur defect performed in this 
study, L-pNIPAM-co-DMAc provided initial support as 
a scaffold between the adjacent bone surfaces, facilitated 
native cell infiltration and graft integration. Together 
with stimulating osteogenic differentiation of native 
osteoprogenitor cells and transplanted stem cells. This is 
shown by the production of early osteogenic markers, to 
promote effective bone augmentation. Therefore in non-
weight bearing situations L-pNIPAM-co-DMAc may 
provide the beneficial properties of both a cell carrier and a 
support scaffold to regenerate and augment bone in clinical 
situations such as periodontal disease [69], increasing bone 
density in osteoporosis [28], aiding fixation of prosthetic 
implants [70] as well as non-union fracture [71], where 
mechanical support is provided by an additional implant. 
A design consideration for the development of 
injectable hydrogels for bone repair, which is often 
regarded as fundamental, is that the developed hydrogel 
must degrade in a controlled manner to enable effective 
load transfer to the newly regenerated bone matrix [71]. 
Scaffold degradation is dependent on the chemical 
and structural properties of the biomaterial, as well as 
several biological factors including mechanical loading, 
pH, temperature, enzymatic activity and rates of tissue 
ingrowth [20, 72]. Therefore scaffold degradation will 
inevitably be patient dependant and therefore designing 
a hydrogel that degrades commensurate with bone in-
growth, remains a significant challenge and a barrier to the 
clinical translation of these treatments. In addition, scaffold 
degradation raises safety issues regarding the toxicity of 
degradation products which may cause tissue dysfunction 
and/or initiate an inflammatory reaction [71]. In the present 
study L-pNIPAM-co-DMAC subcutaneously implanted for 
6 weeks and injected within a femur defect for 4 weeks, 
demonstrated no signs of scaffold degradation and hence 
may avoid some of the issues and complications associated 
with scaffold degradation. Long term in vivo studies within 
a critically sized bone defect are essential to determine 
the long term fate and efficacy of L-pNIPAM-co-DMAc. 
However, it is envisaged that the non-biodegradable 
hydrogel, will facilitate long term scaffold support, whilst 
the newly regenerated bone tissue, will integrate with the 
hydrogel and undergo natural bone tissue remodelling, to 
regenerate a fully integrated and functional bone/hydrogel 
scaffold matrix. 
CONCLUSION
The current study used an injectable L-pNIPAM-
co-DMAc loaded with HAPna and MSCs to induce bone 
healing within a rat femur defect. We have demonstrated 
that the injectable hydrogel is biocompatible, able to 
integrate with surrounding bone tissue and promote 
increased deposition of early markers of bone formation. 
The low viscosity nature of L-pNIPAM-co-DMAc, 
enables its delivery directly into the target site, where 
it can fill both micro and macro fractures. Providing a 
scaffold between adjacent surfaces of bone tissue and 
initial support, facilitate the migration of native cells to 
aid tissue integration as well as promote the osteogenic 
differentiation of transplanted stem cells to regenerate 
and augment a functionally integrated bone matrix. This 
system could potentially provide safe and efficacious 
bone regeneration for the treatment of small bone 
defects in non-union cases as well as clinical cases of 
osteoporosis, fixation of prosthetic implants, spinal fusion 
and periodontal regenerative therapy.
MATERIALS AND METHODS
Hydrogel synthesis
Synthesis of L-pNIPAM hydrogel
An exfoliated suspension of Laponite® clay 
nanoparticles (25–30 nm diameter, <1 nm thickness) (BYK 
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Additives Ltd, Cheshire UK) was prepared by vigorous 
stirring of Laponite® (0.1 g) in deionised H
2
0 (18 MΩ) 
(9.0 mL) for 24 h. N-isopropylacrylamide 99% (NIPAM) 
(0.9 g) (Sigma, Poole, UK) and 2–2ʹ-azobisisobutyronitrile 
(AIBN) (9 mg) (Sigma, Poole, UK) were added to the 
suspension and stirred for 1 h. After passing the suspension 
through 5–8 µm pore filter paper, polymerisation 
was initiated by heating to 80° C and the reagents 
were allowed to react for either 4 h (L-pNIPAM-4h) 
or 24 h (L-pNIPAM-24h), to investigate the effect of 
reduced synthesis time on the biocompatibility of pre-set 
hydrogel constructs following subcutaneous implantation 
(see section 2.2.1). It was observed that after heating 
the monomeric suspension to 80° C, the transparent 
liquid transformed to a milky suspension. Following 4 
(L-pNIPAM-4h) or 24 h (L-pNIPAM-24h) the hydrogel 
suspension was cooled to room temperature which resulted 
in a solidified hydrogel.
Synthesis of L-pNIPAM-co-DMAc with or without 
hydroxyapatite nanoparticles
Synthesis of L-pNIPAM-co-DMAc was performed 
as described previously [18] polymerisation at 80° C 
was performed for 4 h (L-pNIPAM-co-DMAc-4h) or 
24 h (L-pNIPAM-co-DMAc-24h). For hydroxyapatite 
containing hydrogels the L-pNIPAM-co-DMAc was 
cooled to 50° C and hydroxyapatite nanoparticles (HAPna) 
(<200 nm) (Sigma, Poole UK) were homogenously mixed 
into the liquid hydrogel suspension at 0.5 mg/mL as 
describe previously [18]. 
Animals and housing
Animal experiments were performed under Project 
Licences PPL 40/3311and PPL 708054 issued by the 
Home Office under the Animals (Scientific Procedures) 
Act of 1986. Individual protocols and study plans were 
approved by the local Animal Welfare and Ethical Review 
Body. A total of 83 (51 male and 32 female) Wistar rats 
were used in this study. Male rats were supplied by Harlan 
UK and were approximately 12 weeks old at surgery with 
an average weight of 327 g for the subcutaneous model 
and 385 g for the femur model. Female rats used in this 
study were older (>6 months) ex-breeders, obtained from 
(Charles Rivers, Harlow, UK) with an average body 
weight of 411 g at surgery. All animals were of a healthy 
status and were genetically unmodified. All animals 
were housed in groups and kept in standard laboratory 
conditions with free access to food (Teklad Global 18% 
Protein Rodent Diet, Harlan Laboratories, UK) and water. 
In vivo safety: subcutaneous implantation 
Subcutaneous implantation operational procedure
Initial biocompatibility of the hydrogel was 
evaluated by subcutaneous implantation of hydrogel 
constructs in young 10–12 weeks old male Wistar rats for 6 
weeks. Four separate hydrogel batches were investigated: 
L-pNIPAM-4h; L-pNIPAM-24h; L-pNIPAM-co-DMAc-
4h and L-pNIPAM-co-DMAc-24h together with sham 
operated controls (n = 6). Reduced preparation time (4 
or 24 h) was investigated to determine whether hydrogel 
synthesis could be optimised for future in-clinic use. 
Hydrogels for implantation were prepared by pipetting 
300 µl of liquid L-pNIPAM or L-pNIPAM-co-DMAc 
onto sterile petri dishes at RT, resulting in solidified 
cylindrical hydrogel discs (2mm height, 14mm diameter). 
All hydrogel scaffolds were sterilised prior to surgical 
implantation by UV radiation (230V, 50/60Hz, 0.400KW) 
for 15 minutes using TelSTAR mini-V/PCR laminar flow 
cabinet with built in UV light. 
Thirty 12-week old male Wistar rats with an 
average weight of 327 g were used for this investigation. 
Anaesthesia was induced using 5% Isofluorane/O
2
 (Abbott 
Laboratories, Maidenhead, UK) and maintained with 
1.5 – 2% Isofluorane/O
2
. Surgical site was prepared by 
swabbing with Tisept® (Medlock Medical Ltd, Oldham 
UK). A midline incision was made through the skin on 
the back and a pocket developed on the left side by blunt 
dissection. One hydrogel disc was placed in the pocket and 
the wound closed with Vicryl™ sutures (Ethicon™, Johnson 
and Johnson, Livingston, Scotland). Sham operated 
control animals were treated in an identical manner but no 
implant placed. After 6 weeks rats were sacrificed using 
schedule one method and weights recorded. Implantation 
site and organs including: liver; kidney; testes and lymph 
nodes were removed and fixed in 10% w/v neutral 
buffered formalin (nbf) (Leica Microsystems, Milton 
Keynes UK) for histological assessment. 
Blood collection and sample analysis
To investigate evidence of systemic inflammatory 
response or organ pathology, a complete blood count, 
differential blood count and serum biochemistry 
analysis was performed. At sacrifice, ~1.5mL of blood 
was obtained via cardiac puncture and collected into 
three vials: ~1.0mL of blood was collected into EDTA 
vials for full blood count and differential blood count, 
150µL of blood was collected into a serum coagulation 
vial for serum biochemistry analysis and a further 50 
µL was collected into a second serum coagulation vial 
for assessment of c-reactive protein (CRP) (IDEXX 
laboratories, Ludwigsburg, Germany). Haematological 
parameters analysed as part of the full blood count and 
differential blood count included: haemoglobin (g/dL), 
packed cell volume (%), mean cell volume (fL), mean 
corpuscular height (pg), mean corpuscular haemoglobin 
concentration (g/dL), erythrocytes (T/L), leukocytes 
(g/L), lymphocytes (absolute/µL), thrombocytes (g/dL), 
eosinophils (absolute/ µL), band neutrophils (absolute/µL), 
segmented neutrophils (absolute/µL), and monocytes 
(absolute/µL). A differential white blood cell count was 
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also assessed morphologically by blood smears. Serum 
biochemistry parameters investigated included: alkaline 
phosphatase (U/L), albumin (g/L), alanine transferase 
(U/L) and bilirubin (µmol/L) as a measure of liver 
function, as well as creatinine (µmol/L) as a measure 
of kidney function. Samples taken for full blood count 
and differential blood count were shipped at ambient 
temperature and samples for serum biochemistry and 
CRP analysis were shipped on dry ice. All samples 
were analysed independently by IDEXX laboratories 
(Ludwigsburg, Germany). 
In vivo efficacy rat femur defect model 
Experimental design: rat femur defect model in 10–12 
weeks old male Wistar rats
For assessment of hydrogel biocompatibility and 
performance in bone, a healing femur defect model was 
used. A 1mm defect was created in the mid-shaft of the 
right femur of 10–12 week old male Wistar rats (average 
weight 385 g). Animals were divided into four separate 
experimental groups to investigate the efficacy of the 
L-pNIPAM-co-DMAc ± MSCs and HAPna for bone 
repair. The experimental groups were divided as follows: 
Sham operated control; L-pNIPAM-co-DMAc + 2 × 106 
cells/mL rat MSCs; acellular L-pNIPAM-co-DMAc + 0.5 
mg/mL HAPna; or L-pNIPAM-co-DMAc + 2 × 106 cells/
mL rat MSCs + 0.5 mg/mL HAPna (n = 3 per group). 
Experimental design: rat femur defect model in aged 
(>6 months) female ex-breeder Wistar rats
Femur defects were created in female ex-breeder 
Wistar rats (>6 months, average weight at surgery of 411 
g) with the hypothesis that these animals would have a 
reduced or delayed healing capacity which represents the 
aged population which would be targeted for bone repair. 
To test this hypothesis initial experiments investigated the 
healing of sham operated controls in 10–12 week old male 
Wistar rats in comparison to the older (>6 months) female 
ex-breeder Wistar rats (n = 7). Following this, further animal 
surgeries were performed to investigate the efficacy of the 
L-pNIPAM-co DMAc ± MSCs and HAPna for bone repair 
in aged female ex-breeder Wistar rats. The experimental 
groups were: acellular L-pNIPAM-co-DMAc ± 0.5 mg/mL 
HAPna; L-pNIPAM-co-DMAc + 2 × 106 cells/mL rat MSCs 
+ 0.5 mg/mL HAPna (n = 7 for each group). All animals 
were maintained for 4 weeks prior to sacrifice for analysis.
Extraction of rat mesenchymal stem cells
Rat MSCs were isolated from the same breeding line 
of male 10–12 week old male Wistar rats (pooled from 
n = 5) and older (<6 month) female ex-breeder Wistar 
rats (pooled from n = 4). Animals were sacrificed using 
schedule 1 killing. Tibiae and femora were aseptically 
removed, bones dissected to expose marrow space and 
bone marrow flushed out using 18 gauge needle with 
DMEM (Life Technologies, Paisley UK) supplemented 
with 10% v/v heat inactivated foetal calf serum (FCS) 
(Life Technologies, Paisley UK), 100 U/ml penicillin 
(Life Technologies Paisley UK), 100 μg/ml streptomycin 
(Life Technologies Paisley UK), 250 ng/ml amphotericin 
(Sigma, Poole UK), 2 mM glutamine (Life Technologies, 
Paisley UK) and 10 μg/ml ascorbic acid (Sigma, Poole 
UK) (complete cell culture media). Mononuclear 
cells were then isolated as previously described [73] 
using a Histopaque 1077 gradient (Sigma, Poole, UK). 
MSCs (characterised by their adherence to plastic and 
morphology) were then expanded in monolayer and used 
for implantation at passage 2. 
In vivo efficacy rat femur defect operational 
procedure 
Anaesthesia was induced and maintained as 
described above. A single dose of 0.05ml of 50mg/ml 
carprofen (Rimadyl™, Pfizer Ltd, Sandwich UK) was 
given by subcutaneous injection. The right hind limb was 
immobilised and the surgical site prepared by swabbing 
with Tisept®. An incision was made over the right femur 
and bone exposed by blunt dissection; a single defect 
was created using a 1mm diameter stainless steel bur 
with saline irrigation. The defect was either left untreated 
to serve as a sham operated control or injected with 
L-pNIPAM-co-DMAc as described previously (section 
2.2.2.1). Surgical wounds were closed with resorbable 
sutures. Cell seeding solutions were prepared at a density 
of 2 × 106 cells/mL, homogenously mixed with the 
L-pNIPAM-co-DMAc suspension (38–39° C) ± 0.5 mg/
mL HAPna (Sigma, Poole, UK) and injected directly into 
the femur defect via 26-gauge needle injection (Becton 
Dickinson, Plymouth, UK) until the defect cavity was full 
with the implanted hydrogel. Following injection, it was 
observed that the hydrogel solidified rapidly (<5 seconds) 
within the bone defect site. 
Microcomputed tomography
Microcomputed Tomography (Micro-CT) was 
performed 4 weeks after surgery on the defect site in 
the femur using a Bruker SkyScan 1172, images were 
reconstructed with NRecon v1.6.10.4 software and 
analysis performed using CTAn v1.4.0. µCT parameters 
were: X-ray source, 65kV/139uA; rotation 360°; exposure 
time 1180 ms; image pixel size 10 µm; 0.5 µm aluminium 
filter. A cylindrical region of interest (surrounding the 
femur defect) was selected with a diameter of 1mm 
and depth of 1mm, which included the entire defect 
region within the mid-shaft of the femur. Parameters 
for image processing were: ring artefact correction: 10; 
beam hardening correction: 15%; global thresholding: 
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80–225. 3D images of the defect region and new bone 
formation, using double-time cubes algorithm, were 
reconstructed for representation and the bone volume (%) 
was measured. 
Histological assessment of subcutaneous 
implantation site, femur defect site and organs
For histological assessment of hydrogel 
biocompatibility, tissue integration and bone augmentation, 
the implant sites (subcutaneous implant skin region 
and femur defect region) together with vital organs 
were extracted and fixed in 10% w/v formalin (Leica 
Microsystems, Milton Keynes UK) overnight (organs) or 
for 1 week (skin region and femur specimens). The femur 
specimens were then decalcified for 3 weeks in Surgipath 
Decalcifier I (Leica Microsystems, Milton Keynes UK), 
with solution changed every 2 days, prior to routine paraffin 
embedding. Tissue samples were serially sectioned at 
4µm and sections mounted every 100µm onto positively 
charged slides (Leica Microsystems, Milton Keynes UK) 
for histological evaluation throughout the defect region. 
Sections stained with haematoxylin and eosin (H&E) 
Masson’s trichrome as described previously [18]. All 
slides were blinded and independently assessed by a 
histopathologist. 
Immunohistochemistry assessment of femur 
defect site
Immunohistochemistry protein expression of 
the macrophage marker CD68, the early bone markers 
runx2 and alkaline phosphatase, the bone matrix markers 
collagen type I and collagen type X, as well as the late 
bone markers osteopontin and osteocalcin were selected 
for immunohistochemistry (IHC) investigation to assess 
the bone healing response within the rat femur defect 
model following 4 weeks repair time. Sections were 
then prepared as described above; IHC was performed as 
previously described (Table 1) [18]. 
Fourier transform infrared spectroscopy image 
analysis of femur defect sections
Femur specimens were processed and sectioned as 
described above (section 2.5). For FTIR image analysis 
a 4 µm transverse section within the centre of the femur 
defect region was mounted onto gold coated reflective 
slides (Kevley Technologies, Ohio, USA). Mid-infrared 
microscopic images were collected using an Agilent 
680-IR FTIR spectrometer coupled with a FTIR imaging 
microscope. The microscope was fitted with a liquid 
nitrogen cooled 128 × 128 mercury-cadmium-telluride 
focal plane array detector (FPA) and an automated 
sampling stage. Images were collected and processed 
using Resolutions Pro FTIR Spectroscopy software 
version 5.2.0 (Agilent Technologies, UK). FTIR mosaic 
images encompassing the whole of the bone sections were 
collected in transflectance mode by co-adding 128 scans 
at a spectral resolution of 8 cm-1 using a clean region of 
the reflective substrate as a background. Species specific 
images were generated by integrating the peaks ~1738, 
~1660 and ~1460 cm-1, to obtain the distribution of 
L-pNIPAM-co-DMAc, bone tissue and embedding wax 
respectively within each section.
Data analysis, processing and statistical analysis
All slides were examined with an Olympus BX51 
microscope and images captured by digital camera and 
Capture Pro OEM v8.0 software (Media Cybernetics, 
Buckinghamshire, UK). Histological sections were 
analysed, features noted and images captured to document 
their histological appearance. The percentage area of 
collagen staining was assessed on slides stained with 
Masson’s trichrome using image J analysis software 
version 1.5i. The entire defect region (1mm diameter, 
1mm depth) was selected as the region of interest. The 
image was split into red, green and blue using RGB stacks 
and thresholding was applied at a range of 10–120 using 
the red channel which gave the best contrast for blue 
Table 1: Target antibodies used for IHC, their optimal concentrations and antigen retrieval methods [18]
Target Antibody Clonality Optimal Dilution Antigen 
Retrieval
Secondary 
Antibody
Serum 
Block
CD68 Mouse Monoclonal 1:200 Enzyme Rabbit anti mouse Rabbit 
Runx2 Mouse Monoclonal 1:200 Heat Rabbit anti mouse Rabbit 
Alkaline Phosphatase Rabbit 
Polyclonal
1:200 Heat Goat anti rabbit Goat 
Collagen type I Rabbit 
Polyclonal
1:200 Enzyme Goat anti rabbit Goat 
Collagen type X Rabbit 
Polyclonal
1:400 Enzyme Goat anti rabbit Goat 
Osteopontin Mouse Monoclonal 1:200 None Rabbit anti mouse Rabbit 
Osteocalcin Mouse Monoclonal 1:400 Enzyme Rabbit anti mouse Rabbit 
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(collagen) staining; the percentage area of blue staining 
was then measured. 
Evaluation of IHC staining was performed by 
counting immuno positive and immuno negative cells 
for each section and immunopositive cells expressed as a 
percentage of total count.
All tests were performed at least in triplicate. 
Data were assessed for normality using the Shapiro 
Wilks test and found to be non-normally distributed, 
as such data were non-parametric and hence statistical 
comparisons were performed by Kruskal-Wallis for 
pairwise comparisons (Conover-Inman) with statistical 
significance accepted at p ≤ 0.05. Pairwise comparisons 
were made as follows: between all implant conditions for 
blood and biochemistry analysis (Figure 1C), between 
all experimental groups within young 10–12 weeks old 
male rats for micro CT analysis, between all experimental 
groups within aged exbreeder female rats for Micro-CT 
analysis (Figure 4) and between all experimental groups 
within aged exbreeder female rats for % area of collagen 
staining (Figure 5). Statistical analysis of the two groups: 
sham operated young male rats vs sham operated aged 
exbreeder female rats for micro CT analysis was performed 
by Mann–Whitney U test. Data were then presented on 
graphs; all replicates have been shown with median value 
indicated to demonstrate clearly the spread of replicates.
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